Business Context and Reporting Period
Revolution Medicines, Inc. (RVMD) filed a Form 8-K on April 14, 2026, reporting significant capital raising activities. The company, incorporated in Delaware and headquartered in Redwood City, California, executed two major financing transactions in mid-April 2026 to secure liquidity for its operations.
Key Financial Metrics and Transaction Details
- Equity Offering: Sold 10,563,381 shares of common stock at $142.00 per share. Underwriters exercised a full option to purchase an additional 1,584,506 shares.
- Net Proceeds (Equity): Approximately $1,650.4 million after underwriting discounts, commissions, and estimated expenses.
- Convertible Note Offering: Issued $500.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2033.
- Closing Dates: Equity offering closed on April 16, 2026; Convertible Note offering expected to close on April 17, 2026.
- Underwriters: J.P. Morgan Securities LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC.
Material Changes
This filing represents a material change in the company's capital structure and liquidity position. The filing does not provide comparative financial metrics (revenue, profit, or margins) against prior periods as it is a current report focused on a specific transaction rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
The company intends to use the proceeds to fund its business operations and general corporate purposes. The filing includes forward-looking statements regarding the completion of the Convertible Note Offering and the expected net proceeds. Management highlighted risks including market conditions, satisfaction of closing conditions for the notes, and risks detailed in the prospectus supplements and periodic SEC reports. The company does not undertake to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the final closing of the $500 million Convertible Note Offering on or after April 17, 2026.
- Confirm the exact net proceeds received from the equity offering after all expenses are finalized.
- Review the terms of the 0.50% Convertible Senior Notes due 2033, specifically conversion rates and redemption provisions.
- Assess the dilution impact of the total shares issued (approximately 12.15 million shares) on existing shareholders.
- Examine the "Risk Factors" section in the final prospectus supplements filed with the SEC.